Navigation Links
TOPICA Elects G. Kirk Raab as Chairman of the Board
Date:7/16/2009

PALO ALTO, Calif., July 16 /PRNewswire/ -- TOPICA Pharmaceuticals today announced that G. Kirk Raab has been elected chairman of the company's Board of Directors.

"As a pre-eminent leader in the biotechnology industry, and as the former chairman of Connetics Corporation and Oclassen Pharmaceuticals, Kirk Raab brings a proven track record of leadership and success to TOPICA, as well as an exceptional knowledge of the dermatology market," said Greg Vontz, president and chief executive officer of TOPICA. "His addition to our Board builds on our team's extensive experience developing and commercializing significant dermatologic products, and we look forward to working with him."

"Greg and I worked together successfully at Genentech and Connetics Corporation, and I look forward to achieving a similar outcome for TOPICA," said Mr. Raab. "The company is poised for success with its experienced board, management team, significant market potential and novel molecule, luliconazole."

Mr. Raab has more than 45 years of pharmaceutical and biotech experience. For the past 14 years, he has been involved in the management and operations of more than 15 biotech companies, for many of which he served as chairman. He served as chairman of Connetics Corporation, a highly successful dermatology company acquired by Stiefel Laboratories, and most recently was chairman of BiPar Sciences, which was acquired by Sanofi-Aventis. From February 1990 to July 1995, Mr. Raab served as president and chief executive officer of Genentech. He originally joined Genentech in February 1985, as president and chief operating officer. Prior to joining Genentech, Mr. Raab worked for Abbott Laboratories for 10 years, most recently as president, chief operating officer and director. He served as the first chairman of the Biotechnology Industry Organization (BIO) and the California Health Care Institute.

About Luliconazole

Luliconazole, the company's lead product candidate, is one of the most potent and broad spectrum molecules in the imidiazole class of antifungal agents. TOPICA is currently conducting a U.S.-based, Phase 2 trial of luliconazole in patients with tinea pedis (athlete's foot). Tinea pedis is the most common fungal infection of the skin, affecting about one in every 10 people. The company is also developing luliconazole for onychomycosis (nail and nail bed fungal infections). Onychomycosis affects approximately 35 million people in the U.S. Of those affected, an estimated 47 percent are not receiving treatment. The potential annual U.S. market for onychomycosis treatment is estimated at approximately $3 billion. TOPICA has an exclusive license from Nihon Nohyaku Co., Ltd. to develop and market luliconazole in the Americas and Europe.

About TOPICA Pharmaceuticals

TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing potent topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete's foot) and onychomycosis (nail and nail bed fungal infections). For more information, please visit http://www.topicapharma.com.


'/>"/>
SOURCE TOPICA Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
2. Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (Pink Eye)
3. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
4. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
5. Clinical Topicals Makes Breakthrough Migraine Treatment Available Free to Soldiers
6. U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
7. Topical cream studied as way to treat skin cancer without the knife
8. TOPICA Begins Phase 2 Clinical Trial of Potent Antifungal, Luliconazole, in Athletes Foot
9. Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection
10. New Topical Painkiller Relieves Severe Pain in Minutes
11. Topical Dermatological Product Development in the USA Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: